SCHEMBL6071402

SCHEMBL6071402

CC(=O)Nc1ccc2[nH]c3c(c2c1)CC/C(=C/N(C)C)C3=O

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 5/20 0.48
MTNR1A P48039 2/20 0.48
MTNR1B P49286 2/20 0.48
KMT2A Q03164 1/20 0.48
ALDH1A1 P00352 4/20 0.46
HPGD P15428 3/20 0.46
ESR1 P03372 1/20 0.46
RAB9A P51151 5/20 0.45
MAPT P10636 5/20 0.45
SMN1; SMN2 Q16637 3/20 0.45
ERCC1 P07992 1/20 0.45
DNASE1 P24855 1/20 0.45
FEN1 P39748 1/20 0.45
ERCC4 Q92889 1/20 0.45
MAOA P21397 1/20 0.43
PRNP P04156 1/20 0.43
GRM2 Q14416 1/20 0.41
NPC1 O15118 2/20 0.40
POLB P06746 2/20 0.40
LMNA P02545 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6071404 1.00 KDM4E (0.48) KDM4EMTNR1AMTNR1BKMT2AALDH1A1
SCHEMBL6070281 0.86 RAB9A (0.45) KDM4EKMT2AALDH1A1RAB9AMAPT
SCHEMBL6070286 0.86 RAB9A (0.45) KDM4EKMT2AALDH1A1RAB9AMAPT
SCHEMBL6070536 0.83 RAB9A (0.44) KDM4EKMT2AALDH1A1HPGDRAB9A
SCHEMBL6070529 0.83 RAB9A (0.44) KDM4EKMT2AALDH1A1HPGDRAB9A
SCHEMBL13925707 0.79 MAPT (0.53) KDM4EKMT2AALDH1A1HPGDRAB9A
SCHEMBL6070960 0.76 MAPT (0.45) KDM4EKMT2AALDH1A1HPGDRAB9A
SCHEMBL6070963 0.76 MAPT (0.45) KDM4EKMT2AALDH1A1HPGDRAB9A
SCHEMBL6070573 0.76 MAPT (0.56) KDM4EKMT2AALDH1A1RAB9AMAPT
SCHEMBL6070568 0.76 MAPT (0.56) KDM4EKMT2AALDH1A1RAB9AMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060264493-A1 Tetracyclic pyrazole derivatives as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them PFIZER ITALIA S.R.L. (IT) 2006-11-23 US disclosed
EP-1599202-A1 TETRACYCLIC PYRAZOLE DERIVATIVES AS KINASE INHIBITORS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM Pharmacia Italia S.p.A. (IT) 2005-11-30 EP disclosed
WO-2004071507-A1 TETRACYCLIC PYRAZOLE DERIVATIVES AS KINASE INHIBITORS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM PHARMACIA ITALIA S.P.A. (IT) 2004-08-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060264493-A1 Tetracyclic pyrazole derivatives as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them MAP3K1, MAP3K19, MAP3K20 KDM4E 1799/4885MTNR1A 4530/4885MTNR1B 4558/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.